Historic mission from Houston space tech company plans for splashdown

earthbound

Ax-1 is headed back to Earth after 12 days of research on the ISS. Photo courtesy of SpaceX

Editor's note: Undocking was delayed again on April 19, and a new timeline has not been announced. The original story is below.

After spending 12 days in space, a historic commercial space mission will splash back down on Earth this week.

Houston-based Axiom Space’s first mission Axiom mission 1 (Ax-1), which took off April 8 and connected to the International Space Station, has announced its plans for undocking and splashdown.

After some initial bad weather postponed the process, the four-member private astronaut crew now is aiming to undock at about 9 pm tonight, April 19, and then land off the coast of Florida at around 2:24 pm tomorrow, April 20. Just like launch, the coverage of both events will be available at Axiom's website.

The mission on SpaceX’s spacecraft sent four multinational private astronauts — Commander Michael López-Alegría, Pilot Larry Connor, Mission Specialist Eytan Stibbe, and Mission Specialist Mark Pathy — to the ISS to conduct research and familiarize Axiom with launch, docking, and more.

Axiom Space, which reached $1 billion valuation and joined the Houston unicorn club last year after a $130 million investment round, is working on the first commercial space station to replace the ISS. The first launch of that mission is expected in late 2024. In the meantime, Axiom has a series of commercial launches to the existing station currently in orbit in order to prepare for development and orchestration of Axiom Station.

The Ax-1 mission, which has provided daily updates, has conducted over 20 research projects and even hit a few milestones, including:

  • The first-ever music duet performance in space — Commander López-Alegría and Neo-Classical Piano Prodigy BLKBOK made music and space history with their piano and keyboard duet
  • The Aging and Heart Health investigation, an experiment from the Mayo Clinic — a study that analyzes human cells for genetic markers of cellular aging and explores cardiac-like cells' adaptation to microgravity
  • Observation of Transient Luminous Events — Specialist Stibbe completed a space observation experiment and photographed a lightning storm over Darwin, Australia, to enhance understanding of the electrical processes in the atmosphere and to determine whether there’s a connection with climate change
  • Testing of the Holoportation system — Mission Specialist Pathy set up two-way AI technology that will allow the ability of future crew members to explore deep space with the ability to virtually bring friends, family, and physicians close with them so that they can get an on-Earth experience
  • Several outreach calls to Earth to STEM students from around the world — this included a call to children at Space Center Houston

Axiom shares more details on its mission research projects — which span technologies such as future space habitats, cancer research, and devices to purify air on space stations — online.

“As the first step on a path to building a diverse, thriving economy in low-Earth orbit, Axiom has partnered with leaders in academia and industry to bring new users and new investigations in research to the space station,” says Christian Maender, director of In-space Manufacturing and Research for Axiom Space, in a news release. “The collection of biological and technological tests during the Ax-1 mission represent a breadth of research that will inform everything from human health considerations to novel infrastructure and design for our future homes away from Earth, beginning with Axiom Station.”

The four-person crew spent 12 days on the ISS. Photo courtesy of NASA

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings